Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
April 17, 2024 08:00 ET
|
Bionano Genomics
Bionano and Diagens form strategic partnership to commercialize OGM plus AI cytogenetic analysis for reproductive health in China.
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
April 02, 2024 08:00 ET
|
Bionano Genomics
Bionano will unveil new genome analysis solutions for cancer research at the upcoming AACR annual conference in San Diego, California.
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
March 19, 2024 08:00 ET
|
Bionano Genomics
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer...
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
January 19, 2024 08:00 ET
|
Bionano Genomics
26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual exhibition...
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
December 26, 2023 08:00 ET
|
Bionano Genomics
Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal...
Consortium Study Finds Bionano Genomics’ Optical Mapping Essential for Comprehensive Detection of Structural Variants
April 17, 2019 12:00 ET
|
Bionano Genomics
SAN DIEGO, April 17, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and...
Bionano Genomics Launches New Capabilities of the Saphyr System to Significantly Increase Its Cost Effectiveness, Speed and Ease of Use for Whole Human Genome Structural Variation Analysis and Digital Cytogenetics
March 01, 2019 08:00 ET
|
Bionano Genomics
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...